TCRX — Tscan Therapeutics Inc

Tscan Therapeutics Inc (TCRX) is a biotechnology company listed on NASDAQ. It is led by Gavin MacBeath Ph.D., based in 830 Winter Street, Waltham, MA, United States, 02451, with about 138 employees. TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Latest reported TCRX revenue for 2025-09-30 was $2.5M. Net income was -$106.8M. Revenue was down 18.4% from 2025-06-30 to 2025-09-30. TCRX currently screens at market cap $62.1M.

Use this TCRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TCRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TCRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Tscan Therapeutics Inc even when a live quote feed is slow.